Cardinal Health Inc. reported its financial results for the three months ended September 30, 2024, revealing a revenue of $52.3 billion, which represents a 4% decrease from $54.7 billion in the same period last year. This decline was primarily attributed to the expiration of contracts with OptumRx.
In terms of profitability, the company experienced a significant turnaround in GAAP operating earnings, which reached $568 million compared to a loss of $32 million in the prior year. The previous year's results were adversely affected by a $585 million goodwill impairment charge. Non-GAAP operating earnings also saw an increase of 12%, rising to $625 million from $557 million year-over-year.
GAAP diluted earnings per share (EPS) improved markedly to $1.70, up from a loss of $0.05 in the same quarter last year. Non-GAAP diluted EPS increased by 9%, reaching $1.88 compared to $1.72 in the prior year.
The company's cash and equivalents balance at the end of the reporting period was $2.9 billion, a decrease from $5.1 billion as of June 30, 2024. This decline was accompanied by net cash used in operating activities amounting to $1.6 billion.
Breaking down revenue by segment, the Pharmaceutical and Specialty Solutions segment reported $48.0 billion, down 5% from $50.6 billion in the previous year. Conversely, the Global Medical Products and Distribution segment saw a 3% increase in revenue, totaling $3.1 billion. The gross margin for the quarter was $1.9 billion, reflecting a 9% increase from $1.7 billion in the prior year. Additionally, profit from the Pharmaceutical and Specialty Solutions segment rose 16% to $530 million, up from $456 million, contributing to a total segment profit of $642 million, which is a 14% increase from $564 million year-over-year.
During this quarter, Cardinal Health made a significant payment of $366 million related to the National Opioid Settlement Agreement. Furthermore, on September 20, 2024, the company announced an agreement to acquire Integrated Oncology Network for $1.1 billion in cash, marking a strategic development in its growth initiatives.
About CARDINAL HEALTH INC
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.